ЦЗЯН Гуан-Лян (US),ИМ Вха Бин (US),УИЛЕР Ларри А. (US),ВИТКАП Скотт М. (US)
申请号：
RU2013111281/15
公开号：
RU2013111281A
申请日:
2011.08.17
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating corneal haze, by introducing a composition containing a therapeutically effective amount of a compound selected from the group consisting of agonist, EP2 and EP4 agonist, and combinations thereof, whereby the treated rogovitsy.2 blurred. A method according to claim 1, characterized in that corneal opacity caused by photorefractive keratectomy (PRK), laser keratomileusis in situ (LASIK) or laser epithelial keratomileusis (LASEK) .3. A method according to claim 1, characterized in that the compound is an agonist ER2.4. A method according to claim 1, characterized in that the compound is an agonist ER4.5. The method of claim 1, wherein the compound is administered topically using eye drops, ointments, lotions or intraocular implantata.6. A method of treating clouding of the cornea, by introducing a composition containing a therapeutically effective amount of a compound having the structure: wherein each dashed line represents the presence or absence of a double bond R, r and are each independently selected from H or C-Clineynogo alkyl Ryavlyaetsya H, C-Calkilom, C-Calkenilom, a salt thereof or an amine X and Y are each independently selected from H, OH, = O, Cl, Br, I, or CF Z and Zkazhdy is independently selected from CH or N Wi Wkazhdy It is independently selected from CH, CH, or substituted aryl nnogo aryl, heteroaryl, substituted heteroaryl m is 0 to 4 p is 0 or 1 o is 0 to 4 and V is CH, aryl, or substituted aryl, heteroaryl, substituted heteroaryl, wherein the administration treats rogovitsy.7 blurred. A method according to claim 6, characterized in that V is characterized in that Ryavlyaetsya halogen, C-Calkilom or C-Calkenilom n is 0-7 and U represents S or O.8. FROM1. Способ лечения помутнения роговицы глаза, при помощи введения композиции, содержащей терапевтически эффективное количество соединения, выбранного из группы, состоящей из агониста EP2 и агониста EP4 и их комбинации, посредством чего лечат помутнение роговицы.2. Способ по п.
